A Phase 1 Study of BRG01 in Subjects With Relapsed/Metastatic Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma

NCT05864924 | Completed Phase 1 FDA Drug

• 1 other identifier: BIOSG-BRG-01
• Study Type: interventional
• Target: 14
• Locations: 1 country
• Sites: 1

Brief Summary

Phase 1 study evaluating the safety and efficacy of BRG01 in subjects with relapsed/ metastatic EBV-positive nasopharyngeal carcinoma (NPC). BRG01 is a Chimeric Antigen Receptor T-Cell therapy targetting on the specific protein of EBV, which is expressed on the EBV associated cancer cells. This study adopts the traditional "3+3" dose escalation design. Approximately12\~18 EBV+ NPC subjects will be enrolled to evaluate the safety of BRG01. An internal safety review team (SRT) will review the safety data and make recommendations on further study conduct and progression to subsequential cohorts. Subjects will be enrolled into 3 cohorts of different doses, designated as cohort A, B and C.Cohort A: 3.0x10\^6 CAR-T cells/kg,3 subjects, Cohort B: 9.0x10\^6 CAR-T cells/kg,3 subjects, and Cohort C:1.5x10\^7 CAR-T cells /kg, 6 subjects,respectively. Subjects in each cohort will follow the same treatment schedule and procedural requirements.

Conditions

EBV-positive Nasopharyngeal Carcinoma

Outcome Measures

Primary Outcomes (3)

• Dose-Limiting Toxicity (DLT)

  Incidence of adverse events defined as Dose-Limiting Toxicity (DLT).

  From the infusion (Day 0) to Day 28

• Maximum tolerated dose

  The maximum CAR-T dose that can be tolerated in the study.

  From the infusion (Day 0) to Day 28

• AE, SAE, AESI, CRS, ICANS, TEAE

  The incidence of adverse events (AE), serious adverse events (SAE), adverse events of special interest (AESI), cytokine release syndrome (CRS) immune cell associated neurotoxicity syndrome (ICANS) and treatment-emergent adverse events (TEAE).

  The day of leukapheresis to 3 months after infusion

Study Arms (1)

BRG01 injection

EXPERIMENTAL

Intravenous infusion

Biological: Cohort A: 3.0x10^6 CAR-T cells/kg; Biological: Cohort B: 9.0x10^6CAR-T cells/kg; Biological: Cohort C:1.5x10^7 CAR-T cells /kg

Interventions

Cohort A: 3.0x10^6 CAR-T cells/kg BIOLOGICAL

Intravenous infusion

BRG01 injection

Cohort B: 9.0x10^6CAR-T cells/kg BIOLOGICAL

Intravenous infusion

BRG01 injection

Cohort C:1.5x10^7 CAR-T cells /kg BIOLOGICAL

Intravenous infusion

BRG01 injection

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Histologically confirmed nasopharyngeal carcinoma;
• Be able to understand this study and have signed the informed consent;
• Age \>18 years old, \<75 years old;
• Expected survival period ≥3 months;
• Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
• Epstein-Barr virus Encoded RNAs (EBER) positive in tumor tissue detected by in situ hybridization (ISH or FISH):
• By immunohistochemistry (IHC), the target in the pathological sample of the tumor tissue is positive and \>20%;
• According to RECIST v1.1, there is at least one measurable lesion;
• Patients must have failed to response at least 2 lines of the standard therapies recommended by local NPC guidance, and without other therapy available.
• Venous access for apheresis or blood collection can be established, without contraindications for leukapheresis;
• Having adequate organ and bone marrow function, as defined below:
• Complete Blood Count Neutrophils (NEUT#) ≥1.0x10\^9/L; Platelet (PLT) ≥80x10\^9/L; Hemoglobin ≥90g/L; Liver function: Without No liver metastasis Aspartate aminotransferase (AST) ≤2.5 x Upper Limit of Normal (ULN); Alanine aminotransferase (ALT) ≤2.5 x ULN; Total bilirubin (TBIL) ≤1.5 x ULN; Liver Function: With liver metastasis Aspartate aminotransferase (AST) ≤5 x ULN; Alanine aminotransferase (ALT) ≤5 x ULN; Liver Function: With liver metastasis or Gilbert syndrome; Total bilirubin (TBIL) ≤2 x ULN; Creatinine Clearance Rate (CCR) ≥ 50 mL/min; International Normalized Ratio (INR) ≤1.5xULN; Activated partial thromboplastin time (APTT) ≤1.5xULN;
• \. During the study period and within 6 months after the end of administration, the subjects of childbearing potential (whether male or female) must use effective medical contraceptive measures For female subjects of childbearing age, a pregnancy test must be performed within 72 hours before cell infusion, and the result is negative.

You may not qualify if:

• Known or suspected being allergy to any of the agents used in this study.
• Previously received anti-tumor treatments, including other anti-tumor investigational drugs, chemotherapy, immunotherapy, biological agents, hormone therapy, radiation therapy (except local radiation therapy for pain relief), etc., the treatment related toxicity not recovered to baseline or CTCAE≤0\~1.
• Received adoptive cellular immunotherapy (including CAR-T cells and T Cell Receptor-T cells (TCR-T)) within 6months.
• Confirmed central nervous system metastasis.
• Confirmed extensive liver metastasis (the tumor volume is estimated to be≥50% of the total liver volume imaging).
• Clinically significant active infections (e.g. Simple Urinary Tract Infection (UTl), bacterial pharyngitis are allowed) or currently receiving IV antibiotics or have received IV antibiotics with in 14 days prior to enrollment(Prophylaxis antibiotics, antivirals and antifungals are permitted);
• HBsAg positive and Hepatitis B Virus (HBV) DNA copy number positive (quantitative detection ≥1000cps/ml), Hepatitis C Virus (HCV) antibody positive and HCV RNA positive, or HIV positive.
• History of autoimmune diseases (e.g, primary immunodeficiency, inflammatory bowel disease. idiopathic thrombocytopenic purpura, systemic lupus erythematosus, autologous hemolytic anemia, rheumatoid arthritis, etc.).
• The following diseases have not been resolved to CTCAE grade 0-1, 7 days before the conditioning chemotherapy, including: dyspnea, diarrhea, acute or chronic pancreatitis.
• New York Heart Association (NYHA) class 3 or 4.
• Symptoms and sign of cardiovascular diseases, e.g., cardiovascular ischemia, arrhythmias, and heart failure.
• Symptoms and signs of cerebrovascular accidents.
• History of other malignant tumors that cannot be cured within 3 years, except for cervical cancer in situ or skin basal cell carcinoma, and other malignant tumors with a disease-free survival period of more than 5 years.
• Current or expected need for long-term systemic corticosteroid therapy. Note: Topical and inhaled corticosteroids in standard doses and physiologic replacement for subjects with adrenal insufficiency are allowed. Doses of corticosteroids of greater than or equal to 5 mg/day of prednisone or equivalent doses of other corticosteroids are not allowed.
• Subjects of both genders who are not willing to practice birth control from the time of consent through 6 months after the completion.-

Sponsors & Collaborators

• BioSyngen Pte Ltd: lead

Study Sites (1)

Sun Yat-sen University Cancer Center

Guangzhou, Guangdong, 510000, China

Location

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 27, 2023
• First Posted: May 18, 2023
• Study Start: May 10, 2023
• Primary Completion: April 26, 2024
• Study Completion: April 26, 2024
• Last Updated: May 8, 2024

Record last verified: 2023-04

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)